Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 27;13(12):1991-2004.
doi: 10.4254/wjh.v13.i12.1991.

De novo and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation

Ma Ai Thanda Han  1 , Raquel Olivo  2 , Catherine J Choi  3 , Nikolaos Pyrsopoulos  4
Affiliations
Review

De novo and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation

Ma Ai Thanda Han et al. World J Hepatol. .

Abstract

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new acronym adopted from the consensus of international experts. Given the increasing prevalence of MAFLD in pre-transplant settings, de novo and recurrent graft steatosis/MAFLD are common in post-transplant settings. The impact of graft steatosis on long-term outcomes is unclear. The current knowledge of incidence rate, risk factors, diagnosis, long-term outcomes, and management of graft steatosis (both de novo and recurrent) is discussed in this review.

Keywords: De novo; Fibrosis; Graft steatosis; Metabolic dysfunction-associated fatty liver disease; Metabolic dysfunction-associated steatohepatitis; Recurrent; Survival.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: Authors have nothing to disclose.

Figures

Figure 1
Figure 1
Overview of approach and management of post liver transplant metabolic dysfunction-associated fatty liver disease patients. USG: Ultrasound; CT: Computed tomography; TE: Transient elastography; MRS: Magnetic resonance spectroscopy; MRI-PDFF: Magnetic resonance imaging-proton density fat fraction; SWE: Shear wave elastography; MRE: Magnetic resonance elastography.
See this image and copyright information in PMC

References

    1. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-Järvinen H, Fan JG, Grønbæk H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng MH, Fouad Y, Chan WK, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol . 2020;73:202–209. - PubMed
    1. Eslam M, Sanyal AJ, George J, Sanyal A, Neuschwander-tetri B, Tiribelli C, Kleiner DE, Brunt E, Bugianesi E, Yki-järvinen H, Grønbæk H, Cortez-pinto H, Fan J, Valenti L, Abdelmalek M, Romero-gomez M, Rinella M, Arrese M, Eslam M, Bedossa P, Newsome PN, Anstee QM, Jalan R, Bataller R, Loomba R, Sookoian S, Sarin SK, Harrison S, Kawaguchi T, Wong VW, Ratziu V, Yilmaz Y, Younossi Z. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158:1999–2014.e1. - PubMed
    1. Younossi ZM, Stepanova M, Ong J, Trimble G, AlQahtani S, Younossi I, Ahmed A, Racila A, Henry L. Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States. Clin Gastroenterol Hepatol . 2021;19:580–589.e5. - PubMed
    1. Davidson JA, Wilkinson A International Expert Panel on New-Onset Diabetes after Transplantation. New-Onset Diabetes After Transplantation 2003 International Consensus Guidelines: an endocrinologist's view. Diabetes Care. 2004; 27: 805-812. - PubMed
    1. Pham PT, Pham PM, Pham SV, Pham PA, Pham PC. New onset diabetes after transplantation [NODAT]: an overview. Diabetes Metab Syndr Obes . 2011;4:175–186. - PMC - PubMed